SGF29: A Protein with Unique Coiled-Coil Domain and Potential as A Drug Target Or Biomarker

Target Name: SGF29

NCBI ID: G112869

SGF29

SGF29: A Protein with Unique Coiled-Coil Domain and Potential as A Drug Target Or Biomarker

SGF29, also known as Coiled-coil domain-containing protein 101, is a protein that is expressed in a variety of tissues throughout the body. It is characterized by a unique coiled-coil domain, which is a type of protein structure that can cause the protein to adopt a specific shape. This shape is thought to play a role in the function of the protein, as well as its potential as a drug target or biomarker.

The protein encoded by the SGF29 gene is a member of the SGF2 family, which is characterized by a similar coiled-coil domain. This family of proteins is thought to function in a variety of ways, including modulating cell signaling pathways and influencing tissue development and regeneration.

One of the key features of the SGF29 protein is its coiled-coil domain. This domain is composed of a series of amino acids that are arranged in a specific order to form a helic acid structure. When the protein is expressed in cells, the coiled-coil domain is thought to play a role in the regulation of various cellular processes, including cell signaling, cytoskeletal organization, and DNA replication.

In addition to its unique coiled-coil domain, SGF29 also has several other features that make it a potential drug target or biomarker. For example, it is a protein that is expressed in a variety of tissues throughout the body, including the brain, heart, and kidneys. This suggests that it may be involved in a variety of physiological processes that are relevant to a wide range of diseases.

Another potential mechanism by which SGF29 may be targeted by drugs is its role in cell signaling pathways. Many diseases, including cancer, are caused by the misregulation of cell signaling pathways. SGF29 is thought to be involved in the regulation of several signaling pathways, including the TGF-β pathway and the Wnt pathway. This suggests that it may be a useful target for drugs that are designed to inhibit these signaling pathways.

In addition to its potential as a drug target, SGF29 may also be used as a biomarker for a variety of diseases. For example, it has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and prostate cancer. This suggests that it may be a useful biomarker for these diseases, and that its levels may be able to be used as a diagnostic marker.

Overall, SGF29 is a protein that is characterized by its unique coiled-coil domain and its involvement in a variety of physiological processes throughout the body. Its potential as a drug target or biomarker makes it an attractive target for further research and development. Further studies are needed to fully understand the role of SGF29 in cell signaling pathways and its potential as a therapeutic agent.

Protein Name: SAGA Complex Associated Factor 29

Functions: Chromatin reader component of some histone acetyltransferase (HAT) SAGA-type complexes like the TFTC-HAT, ATAC or STAGA complexes (PubMed:19103755, PubMed:20850016, PubMed:26421618, PubMed:21685874, PubMed:26578293). SGF29 specifically recognizes and binds methylated 'Lys-4' of histone H3 (H3K4me), with a preference for trimethylated form (H3K4me3) (PubMed:20850016, PubMed:26421618, PubMed:21685874, PubMed:26578293). In the SAGA-type complexes, SGF29 is required to recruit complexes to H3K4me (PubMed:20850016). Involved in the response to endoplasmic reticulum (ER) stress by recruiting the SAGA complex to H3K4me, thereby promoting histone H3 acetylation and cell survival (PubMed:23894581). Also binds non-histone proteins that are methylated on Lys residues: specifically recognizes and binds CGAS monomethylated on 'Lys-506' (By similarity)

The "SGF29 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SGF29 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets